Targeted Protein Degraders – Key Strategies to Maximize VC Funding and Clinical Success
Targeted protein degraders (TPD) have recently emerged as a novel class of small molecules with the potential to expand the scope of druggable targets, thereby improving the outcomes of diseases. This has stimulated investor interest, leading to the launch of several companies developing TPDs that have raised over $2 billion in the past few years. However, these companies are not immune to market conditions and must now demonstrate that their scientific results translate into the developability of a drug product while also establishing its clinical safety and efficacy. To achieve this, it is critical to establish a solid development pathway that addresses the drug molecule’s risks related to bioavailability, drug metabolism and pharmacokinetics (DMPK) properties, target selection, safety, efficacy, manufacturing, and market factors like disease indication and patient’s preferred route of administration.
In this panel discussion, experts will explore the current investment and clinical landscape of TPD. They will provide insights on how to best position TPD to attract VC funding, how TPD have distinct advantages over more traditional inhibiting drugs, and the importance of tailored developability assessment in identifying lead TPD candidates with high likelihood of clinical success.
Key learning objectives
- Gain insights into the latest trends in venture capital funding and understand the key parameters investors consider when evaluating potential investments in targeted protein degraders.
- Stay updated on the current clinical progress of TPD.
- Understand the concept of molecule developability and its critical role in providing insights into whether the drug candidate has the potential to progress successfully through preclinical studies and clinical trials.
